Safety of ibogaine administration in detoxification of opioid-dependent individuals: a descriptive open-label observational study.
Addiction (Abingdon, England) January 1, 2022 Thomas Knuijver, Arnt Schellekens, Maarten Belgers et al. 49 citations
A single dose of ibogaine (10 mg/kg) in 14 patients with opioid use disorder caused an average QTc prolongation of 95 ms (range 29–146 ms); half of the subjects reached a QTc over 500 ms. No life-threatening cardiac events occurred, but severe temporary ataxia (inability to walk without support) was universal. Withdrawal and psychomimetic effects were mostly manageable; 11 of 14 patients did not return to morphine within 24 hours. The findings indicate that ibogaine induces clinically relevant but reversible QTc prolongation, bradycardia, and severe cerebellar toxicity.